Navigation Links
BioMarin Announces Second Quarter 2011 Financial Results
Date:7/28/2011

t an expanded cohort of patients at the maximum tolerated dose.  The company has cleared a safety review after dosing the 5 mg/kg cohort and has authorization to start enrolling patients at 10 mg/kg.  Top-line results are expected in the second half of 2012.
  • BMN-673 (PARP inhibitor):  BioMarin has two ongoing trials for BMN-673.  In the first quarter of 2011, the company initiated a Phase I/II open-label trial of once daily, orally administered BMN-673 for advanced or recurrent solid tumors.  In July 2011, the company initiated a Phase I, two-arm, open-label, dose escalation study for BMN-673 for the treatment of patients with advanced hematological malignancies.  The primary objective of the studies is to establish the maximum tolerated dose of daily oral BMN-673 and to obtain preliminary efficacy data in an expanded cohort of patients with genetically-defined tumors.  

  • Preclinical Programs

  • BMN-111 for Achondroplasia: Regulatory interactions are underway, and BioMarin expects to initiate a Phase I trial by the first quarter of 2012.  BMN-111 is an analog of C-type Natriuretic Peptide (CNP), a small cyclic peptide that is a positive regulator of bone growth, for achondroplasia, the most common form of dwarfism.  There are approximately 18,000 to 24,000 patients in the U.S. and Europe, an estimated 25 percent of which could be candidates for treatment with a product like BMN-111.
  • Other early stage programs: BioMarin is working on multiple early development opportunities.

  • Non-GAAP Financial Information and ReconciliationThe above results for the three and six months ended June 30, 2011 and June 30, 2010 and financial guidance for the year ending December 31, 2011 are presented both as determined in accordance with GAAP and on a non-GAAP basis. As used in this release, non-GAAP income is based on GAAP Earnings Before Interest, Taxes, Depreciation
    '/>"/>

    SOURCE BioMarin Pharmaceutical Inc.
    Copyright©2010 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7 8 9 10 11 12 13

    Related medicine technology :

    1. BioMarin Partner AnGes MG, Inc. Submits BLA to Japanese Ministry of Health
    2. BioMarin Announces FDA Approval for Kuvan
    3. BioMarin Initiates Phase 1 Clinical Study of PEG-PAL in PKU
    4. BioMarin Announces Positive Results From Phase 2A Clinical Study of 6R-BH4 in Sickle Cell Disease
    5. BioMarin Initiates Phase 1/2 Clinical Trial for GALNS for Morquio A Syndrome
    6. BioMarin Initiates Phase 2 Clinical Study of PEG-PAL in PKU
    7. BioMarin Acquires Huxley Pharmaceuticals, Inc.
    8. BioMarin to Present at the Oppenheimer Healthcare Conference
    9. BioMarin Announces Third Quarter 2009 Financial Results
    10. BioMarin to Acquire LEAD Therapeutics
    11. BioMarin to Present at the Credit Suisse Healthcare Conference
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:8/29/2014)... , Aug. 29, 2014 Thoratec Corporation (NASDAQ: ... mechanical circulatory support therapies to save, support and restore ... the 2014 Morgan Stanley Global Healthcare Conference on Wednesday, ... President and Chief Executive Officer, will provide an update ... Time (9:55 a.m., Pacific Daylight Time).   ...
    (Date:8/29/2014)... 29, 2014 Research and Markets  has announced ... Insight 2014" report to their offering. ... one of the largest segments of pharmaceuticals industry. The numbers ... the available therapies were unable to meet the market requirements. ... for CNS disorder, especially over the past two decades. The ...
    (Date:8/29/2014)... Md. , Aug. 29, 2014  United Therapeutics ... the U.S. District Court for the District of ... favor in the company,s case against Sandoz, Inc. regarding ... Peter Sheridan ruled that U.S. Patent No. ... and enjoined Sandoz from marketing its generic product until ...
    Breaking Medicine Technology:US CNS Disorders Drug Pipeline Insight 2014 2District Court Decision Received In Remodulin Patent Case 2
    ... July 27, 2011 Reportlinker.com announces that ... in its catalogue: India ... Till 2016 http://www.reportlinker.com/p0575381/India-Cardiac-Catheters-and-Guidewires---Market-Trends-Till-2016.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Surgical_Equipment ... This market report provides vital ...
    ... 26, 2011 Symmetry Medical Inc. (NYSE: SMA ... orthopaedic device industry and other medical markets, announced today that ... period ending July 2, 2011 before the market opens on ... conference call at 8:00 a.m. ET on Thursday, August 4, ...
    Cached Medicine Technology:India Cardiac Catheters and Guidewires - Market Trends Till 2016 2India Cardiac Catheters and Guidewires - Market Trends Till 2016 3Symmetry Medical to Report Second Quarter 2011 Financial Results on August 4, 2011 2
    (Date:8/31/2014)... 01, 2014 In order to celebrate the ... announced its latest designs and launched a big promotion. Now, ... , All the company’s new cars are made with ... for the global customers. As a matter of fact, it ... items. Those who are in need of cheap cars can ...
    (Date:8/31/2014)... 2014 LabDoor.com tests the purity and ... According to their website, “We buy products in the ... stores and online sites. No manufacturer-supplied samples are permitted ... Healthy with LabDoor,” a recent study was performed on ... in the United States for Vitamin D3 content, heavy ...
    (Date:8/31/2014)... (PRWEB) August 31, 2014 In the ... of states have proposed legislation to require mandatory labeling ... can make informed purchasing decisions that affect their own ... industry leader advocating for stringent measures to eliminate GMOs ... its “Information, Communication, Engagement” (I.C.E.) initiative with the objective ...
    (Date:8/31/2014)... (PRWEB) August 31, 2014 Twin to twin ... Aiden and Blake Colp before they were born, but an innovative ... gave them the chance at life. , Now, their parents ... the life-saving fetal surgery option available in St. Louis at the ... nights at Market Pub House (6655 Delmar Blvd, St Louis, ...
    (Date:8/31/2014)... Tickets for Brazil vs. Ecuador at MetLife Stadium ... is great news for diehard soccer fans who would have loved ... delight of soccer fans in the Tri-State area these two international ... 9th. , MetLife Stadium is the home field for ... National Football League. The venue opened in 2010 and has already ...
    Breaking Medicine News(10 mins):Health News:#1 Rank Awarded to NutriGold’s Vitamin D3 Gold Supplement for the "Best Value" in Vitamin D 2Health News:#1 Rank Awarded to NutriGold’s Vitamin D3 Gold Supplement for the "Best Value" in Vitamin D 3Health News:#1 Rank Awarded to NutriGold’s Vitamin D3 Gold Supplement for the "Best Value" in Vitamin D 4Health News:NutriGold Announces its I.C.E. Initiative to Educate Consumers about GMOs in Dietary Supplements 2Health News:NutriGold Announces its I.C.E. Initiative to Educate Consumers about GMOs in Dietary Supplements 3Health News:After a Rare Diagnosis Threatened Their Boys’ Lives, Parents Build Awareness About TTTS and Fetal Surgery Options at The SSM St. Louis Fetal Care Institute. 2Health News:After a Rare Diagnosis Threatened Their Boys’ Lives, Parents Build Awareness About TTTS and Fetal Surgery Options at The SSM St. Louis Fetal Care Institute. 3Health News:Brazil vs. Ecuador Tickets MetLife Stadium: Ticket Down Slashes Ticket Prices on Ecuador vs. Brazil Tickets in East Rutherford, NJ at the MetLife Stadium 2
    ... The bastion of the diagnostic company, Medlab, seems to ... an Australian Company, which has been the recipient of ... by the district health boards in Auckland, scheduled to ... Australasia Royal College of Pathologists find themselves in a ...
    ... have known that a woman’s natural hormone levels can ... study from the University of Southern California// (USC)// has ... women varies by ethnicity and race, and may explain ... study appears in the October issue of Cancer Epidemiology, ...
    ... index (BMI) received lower scores on cognitive tests than middle-aged ... the// October 10, 2006, issue of Neurology, the scientific journal ... investigated the relationships between BMI and cognitive function in 2,223 ... four cognitive tests. The participants, who were between the ages ...
    ... to assist HIV infection, may aid the fight against malaria, ... already in use to combat HIV is need of the ... new genre of anti-malarial drugs. ,This is indeed ... and also befalling the HIV afflicted lot with uncanny regularity. ...
    ... holding a world of cures tucked in its many ... right// ingredients needed to nip breast cancer cells in ... discovered in the compound called indole-3-carbinol (I3C), found in ... cancer cells when combined with conventional chemotherapy drugs. By ...
    ... change in Egypt in spite of the extensive awareness campaigns, ... flu, since May.// ,A woman in the northern ... aggressive form of bird flu virus, H5N1. ,According ... was suffering from high fever and shortness of breath. She ...
    Cached Medicine News:Health News:Ethnic Variations in Hormone Levels May Cause Differences in Breast Cancer Risk 2Health News:High BMI Tied to Poor Cognitive Function in Middle-Aged Adults 2
    ... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
    ... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
    ... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
    ... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
    Medicine Products: